PRESS-RELEASE ·Filed Apr 21, 2026
Press release · Earnings
Actionable Insight ▼ Bearish
The stock may react negatively to the prior EPS miss despite this clinical update. Monitor upcoming financial filings for cash runway and R&D spend trends, as the company remains pre-revenue.
Final — all horizons settled through T+60d
RZLT ▲ +33.23% at T+60d
SHORT call ✗ call lost -33.23% · α vs SPY -26.33% · entry $3.28 → $4.37
T+1d
+1.52%
call -1.52% · α -0.51%
$3.33
settled 6mo ago
T+5d
-6.40%
call +6.40% · α +7.49%
$3.07
settled 6mo ago
T+20d
-1.22%
call +1.22% · α +6.13%
$3.24
settled 5mo ago
T+60d
+33.23%
call -33.23% · α -26.33%
$4.37
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Rezolute (RZLT) announced clinical data presentation at an upcoming medical conference but did not report financial results. The earnings context shows a significant EPS miss of -30.5% versus consensus, though no new financials were released in this press release.
Key Financial Metrics
EPS
−$0.22
est −$0.17 · -30.6%
Revenue
$0.00
est $0.00 · 0.0%
Rating
strong miss
Key Facts
- No financial results were released in this press release; only clinical trial data updates for ersodetug were announced.
- Earnings context indicates a prior EPS of $-0.22 vs. consensus of $-0.17, representing a 30.5% miss.
- Revenue was $0, in line with expectations for this pre-commercial biotech company.
- Company to present Phase 3 sunRIZE study data at the Pediatric Endocrine Society Annual Meeting.
Financial Impact
EPS miss of $-0.22 vs. estimate of $-0.17; revenue $0
epsrevenue
Risk Factors
- Continuing negative EPS and lack of revenue generation
- Clinical trial results may not translate into regulatory approval or commercial success
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277771 |
13 reports for RZLT
75% Hit rate @ T+20 Went positive at some point 4 of 4 best @ T+60▲ +26.00%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | DEF 14A | $3.86 | awaiting T+20 | — | $4.11 (+6.48%) |
Oct 14, 2026 13d ago | 8-K | $3.90 | awaiting T+20 | — | $4.11 (+5.38%) |
Oct 5, 2026 22d ago | 8-K | $4.33 | awaiting T+20 | — | $4.11 (−5.08%) |
Sep 24, 2026 4w ago | 8-K | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.11 (−5.38%) |
Sep 24, 2026 4w ago | Press Release | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.11 (−5.38%) |
Jul 21, 2026 14w ago | Press Release | $5.09 $4.66 | ▼ −8.45% | ▼ −11.01% | $4.11 (−19.25%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.86 $5.13 | ▲ +32.90% | ▲ +31.01% | $4.11 (+6.48%) |
Jun 4, 2026 20w ago | Press Release | $4.51 $4.91 | ▲ +8.87% | ▲ +10.24% | $4.11 (−8.87%) |
Jun 2, 2026 21w ago | 8-K | $4.00 $4.95 | ▲ +23.75% | ▲ +25.32% | $4.11 (+2.75%) |
May 12, 2026 24w ago | 8-K | $3.33 $3.86 | ▲ +15.92% | ▲ +16.53% | $4.11 (+23.42%) |
Showing 10 of 13
US Market Status
Market Closed — Opens Thu (9h 39m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers